These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Re: Design and endpoints of clinical trials in hepatocellular carcinoma. Di Maio M; Daniele B; Gallo C; Perrone F J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679 [No Abstract] [Full Text] [Related]
24. Standardization, more funds on horizon for clinical trials. McNeil C J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874 [No Abstract] [Full Text] [Related]
25. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846 [TBL] [Abstract][Full Text] [Related]
28. A 25-year review of sequential methodology in clinical studies. Todd S Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691 [TBL] [Abstract][Full Text] [Related]
29. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products. Brodniewicz-Proba T Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic vaccine trails in Thailand. Churdboonchart V J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562 [TBL] [Abstract][Full Text] [Related]
31. [A combination phase I/II study--dose escalation plan]. Yamamoto N Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175 [TBL] [Abstract][Full Text] [Related]